FRM
LENZ

Fox Run Management’s LENZ Therapeutics LENZ Stock Holding History

Fox Run Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,739
Closed -$252K – 1294
2025
Q4 		$252K Buy
+15,739
New +$459K 0.04% 743

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Fox Run Management's LENZ Position: Q1 2026 in Review

Fox Run Management sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 15,739 shares — an estimated $252K sold.

Fox Run Management first reported a position in LENZ in Q4 2025 and held it in 1 quarter. The position peaked at $252K in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Fox Run Management reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fox Run Management sold 15,739 LENZ Therapeutics shares in Q1 2026, an estimated $252K.
  • Fox Run Management first reported a position in LENZ Therapeutics in Q4 2025 and held it in 1 quarter.
  • Fox Run Management's LENZ Therapeutics position peaked at $252K in Q4 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.